

Supplemental table 1: Baseline demographics of women assessed for CMV shedding

	(n=96)
Enrollment age (years)	
20-29	23 (24%)
30-39	41 (43%)
40-49	24 (25%)
50+	8 (8%)
Pre-ART viral load (copies/mL)	
< 10,000	15 (16%)
10,000-100,000	34 (35%)
100,000-1,000,000	41 (43%)
>1,000,000	6 (6%)
Pre-ART CD4 count (cells/uL)	
<200	40 (42%)
>200	56 (58%)
Trial arm	
Placebo	53 (55%)
Acyclovir	43 (45%)

ART: antiretroviral therapy.

Supplemental figure 1: Average levels of vaginal CMV DNA of all women with detectable shedding for each individual monthly visit (A) and by ART status (0=No ART, 1=ART; B) are shown. Box plots show mean and 95% confidence interval.

